
Missed Target Treatment Times May Increase MI Mortality
Benchmarks for percutaneous coronary intervention, the standard of care for acute ST-elevation MI (STEMI), aren't being met in some cases. Delays in care in the key metric of the time from first contact with medical care to angioplasty with stenting resulted in worse patient outcomes and were associated with increased in-hospital mortality risk in some cases, according to the findings, published on June 11 in JAMA Cardiology .
'There are two categories of patient delays: Those that are patient-centered and those that are system-centered,' said Neal S. Kleiman, MD, Houston Methodist DeBakey Heart and Vascular Center, Houston, the senior author of the new study. 'We don't have control over patient-related factors, but there is a lot we can do in terms of hospital systems.'
For the retrospective cross-sectional study, Kleiman and his colleagues analyzed data on 73,826 patients with STEMI or STEMI equivalent from 503 sites across the United States. The goal was to determine site-level variability in patterns of treatment times and clinical outcomes from 2020 to 2022 based on an analysis of data from the American Heart Association's Get With the Guidelines — Coronary Artery Disease registry — a quality improvement program for patients with coronary artery disease, acute MI and chest pain. The authors said the study is the first large-scale analysis of treatment goals and outcomes in STEMI based on hospital performance.
The researchers found an association between failure to reach the target time from first medical contact with care to angioplasty with stenting — 90 minutes or less — and increased risk for in-hospital mortality for primary presentations and transfers (adjusted odds ratio, 2.21; 95% CI, 2.02-2.42, and 2.44; 95% CI, 1.90-3.12, respectively).
Low-performing hospitals were associated with increased risk for mortality and longer stays in the hospital than were high-performing hospitals. However, hospital location and case volume were not associated with worse outcomes.
The guidelines recommend a target time from first contact with care to angioplasty with stenting of 90 minutes or less for patients presenting directly to hospitals offering angioplasty with stenting and 120 minutes or less for patients requiring transfer to a facility offering the procedure. The study findings revealed significant variability between hospital sites in meeting the key metric of the recommendations — adherence in at least 75% of patients with STEMI. At hospitals with the capability to perform angioplasty with stenting, the target was met in 72.2% of patients at high-performing sites, 60.8% at intermediate-performing sites, and 46.0% at low-performing sites.
When patients required transfers to other facilities with the capability to perform angioplasty, a target first medical contact-to-device treatment time of 120 minutes or less was achieved in 72.3% of patients at high-performing sites, 48.8% at intermediate performing sites, and 21.9% at low-performing sites, according to the researchers. In these hospitals, treatment delays were caused primarily by longer stays in the emergency department and time from arrival in the catheterization laboratory to stenting.
Limitations of the study included the fact registry responses were provided on a voluntary basis and may not reflect the totality of STEMI care in all geographical areas, according to the researchers. The analysis also lacked data on follow-up after discharge, making it difficult to extrapolate the findings over the long term, they said.
Yasser M. Sammour, MD, MSc, cardiology fellow at Houston Methodist DeBakey Heart and Vascular Center, who led the work, said several decades of research have highlighted the importance of treating patients with STEMI efficiently. A previous registry study found fewer treatment delays were linked to reduced mortality.
'The current study tried to take that research one step further, assessing how factors such as hospital performance and location affect patient outcomes,' Sammour said.
The result, he said: 'We're still underperforming. We need to have coordinated strategies with local intervention at the hospital level to examine where significant delays in percutaneous coronary intervention time are occurring.'
The absence of uniformity in established performance measures such as time to initiate treatment in STEMI has led to calls for greater adherence to current recommendations.
In an editorial accompanying the journal article, Roxana Mehran, MD, Mount Sinai Fuster Heart Hospital in New York City, wrote: 'After two decades of data collection, national initiatives, and public accountability, the next step must involve tailored solutions addressing barriers within each institution. Bridging the gap now requires renewed efforts and commitments to prioritize timely, coordinated STEMI care. Until then, the clock will continue to tick — against our patients.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
an hour ago
- Wall Street Journal
Podcast: Nike, Lululemon Shares Rise After Trump Touts Vietnam Trade Deal
Elsewhere in the markets, Centene shares tumble after the healthcare company says its earnings will fall short of expectations. Modelo brewer Constellation Brands expects President Trump's new tariffs to increase its costs by $20 million this fiscal year. 🎧 Listen: Ariana Aspuru hosts the WSJ's Minute Briefing podcast.
Yahoo
2 hours ago
- Yahoo
Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its Overweight rating and $328 price target for Amgen Inc. (NASDAQ:AMGN) in response to the company's disclosure of comprehensive MariTide tolerability data. 360b / The obesity medication's gastrointestinal tolerability profile unnerved the market, particularly the frequency of nausea and vomiting, which at first seemed more problematic than alternatives. Piper Sandler's study however, shows that both one- and two-step dose escalation regimens showed a noticeable improvement in the drug's tolerability profile, consistent with management's claims at the December top-line results announcement. According to the firm, the weight loss drug could produce a more commercially acceptable nausea and vomiting profile due to the much lower starting dosages and three-step dose escalation protocols included in the pivotal studies. Amgen Inc. (NASDAQ:AMGN) is a global biopharmaceutical company that focuses on human treatments for cardiovascular, hematology, inflammation, cancer, and bone health. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Vogue
2 hours ago
- Vogue
Is It Ever Possible to Tan Responsibly?
Hold up—is tanning making a comeback? Robert F. Kennedy, the Secretary of the United States Department of Health and Human Services and leader of the Make America Healthy Again movement, was recently spotted leaving a Washington, D.C. tanning salon Palm Beach Tan. A representative pleaded the fifth, however, on whether Kennedy was there for a spray tan, 20 minutes in the bed with deep dark intensifyer, or on official government business. And a new form of blush, which mimics a sunburn across the nose, is trending, while the models at Chloé's SS25 show were sporting tan lines. That's all on top of the SPF skepticism era we're currently living in: influencers are touting homemade sun protection that has no scientific backing, and skin cancer—an incredibly preventable cancer when preventative measures are taken—has become endemic. Truly, what gives? Board-certified dermatologist Anetta Reszko, MD, gets it. 'I grew up during a time when tanning was completely normalized and, in many ways, encouraged,' she confesses to Vogue. 'I didn't fully understand the long-term consequences of UV exposure until later in my medical training.' For those who are full-blown MAHA, the fact that almost half of Americans are deficient in vitamin D, also known as the 'sunshine vitamin,' may have something to do with it, too. 'There's also a growing appreciation for the psychological and biological benefits of sun exposure—from mood elevation and circadian rhythm support to vitamin D synthesis,' Dr. Resko adds. 'This all influences everything from immune resilience to metabolic health. In that context, sunlight is being reframed as an essential, healing force—part of a broader 'back to basics' wellness trend.' It's not about being anti-sun, it's about being anti-skin cancer. So safety is key—and in fact, there are ways to tan safely. 'The risk of tanning is not equal among everyone,' Manhattan-based board-certified dermatologist Elyse M. Love, MD, says. 'When it comes to skin cancer, the most important thing is to avoid burning. The second most important thing is to decrease cumulative sun exposure.' Dr. Resko agrees. 'You can enjoy the sun and protect your skin. Healthy skin isn't about extremes—it's about consistency and informed choices.'